Disruptive behavior disorder

Summary

Disruptive behavior disorder (MONDO:0800106) is a disease and 21 clinical trials. Top therapeutic interventions include risperidone. A subtype of mental disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 21

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	disruptive behavior disorder
Mondo ID	MONDO:0800106
NCIT	C99753
UMLS	C0012734
MedGen	41619
Is cancer (heuristic)	no

Also known as: disruptive disorder

Disease family

This is a subtype of mental disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder › disruptive behavior disorder

Related subtypes (13): akinetopsia, cortical deafness, pain agnosia, tactile agnosia, visual agnosia, psychosexual disorder, drug-induced mental disorder, alcohol-induced mental disorder, adjustment disorder, mood disorder, psychotic disorder, developmental disorder of mental health, anxiety disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 21.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	16
PHASE3	3
PHASE1/PHASE2	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00236470	PHASE3	COMPLETED	A Study of the Safety of Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders
NCT00250354	PHASE3	COMPLETED	A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation
NCT00266552	PHASE3	COMPLETED	A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation
NCT01750996	PHASE1/PHASE2	COMPLETED	Strongest Families Finland Canada: Family-based Prevention and Treatment Program of Early Childhood Disruptive Behavior
NCT02824627	PHASE2	COMPLETED	Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders
NCT02812537	Not specified	RECRUITING	Clinical and Social Trajectories of Children and Adolescents With Disruptive Behavior
NCT06373484	Not specified	RECRUITING	Matching Assessment and Treatment for Children With Disruptive Behaviour and Their Parents
NCT06626750	Not specified	ACTIVE_NOT_RECRUITING	Evaluating Stress Management Strategies Within the School Readiness Parenting Program
NCT01463241	Not specified	COMPLETED	Behavioral and Affective Skills in Coping (BASIC) Open Trial
NCT02191956	Not specified	COMPLETED	Technology to Enhance Treatment for Early Conduct Problems in Low Income Families
NCT02488499	Not specified	COMPLETED	Addressing Behaviour and Treatment Effectiveness Project (A.B.A.T.E. Project)
NCT02543359	Not specified	COMPLETED	A Statewide Trial to Compare Three Training Models for Implementing an Evidence-based Treatment (EBT)
NCT02704221	Not specified	COMPLETED	Enhancing the Outcomes of a Behavioral Parent Training Intervention
NCT02783560	Not specified	COMPLETED	Behavioral Sleep Intervention in Children With Disruptive Behaviors
NCT03698240	Not specified	COMPLETED	Mindfulness-based Program for Children With Disruptive Behavior Disorder
NCT03796663	Not specified	COMPLETED	Mindful Parenting and Parent Training Program Study
NCT04113161	Not specified	UNKNOWN	Navigating Resource-Constrained Systems and Communities to Promote the Behavioral Health of Black Youth
NCT04113304	Not specified	COMPLETED	The Parenting Young Children Check-up: Proof-of-Concept Trial
NCT04298437	Not specified	COMPLETED	Addressing Depression and Positive Parenting Techniques (ADAPT)
NCT05425381	Not specified	UNKNOWN	Improving Social, Emotional, Behavioral, and Academic Functioning
NCT07495683	Not specified	COMPLETED	Personalizing Psychosocial Intervention for Children With Disruptive Behaviour

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
RISPERIDONE	4	3